» Articles » PMID: 25202360

Short Hairpin RNA of Frizzled-2 Suppresses the Proliferation of Hepatocellular Carcinoma Cells

Overview
Journal Oncol Lett
Specialty Oncology
Date 2014 Sep 10
PMID 25202360
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, Frizzled-2 (Fz2), a receptor of the Wnt ligand, was investigated as a potential target of molecular therapy for hepatocellular carcinoma (HCC). Quantitative polymerase chain reaction (PCR) was performed to determine the expression levels of Fz2. A surgical specimen of HCC was immunostained with an Fz2 antibody. A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt assay was performed on HCC cell lines, including HLF and Hep3B, 72 h after the transfection of the short hairpin (sh)RNA of Fz2 (shRNA-Fz2). RNA was isolated from the Hep3B and HLF cells 48 h after transfection and subjected to quantitative PCR. All cell lines had elevated levels of Fz2 compared with those in an adult liver. The highest and lowest expression levels of Fz2 were 246.9±15.7 in the HLF cells and 5.8±1.4 in the Hep3B cells, respectively. Fz2 was expressed in the tumorous HCC tissue, but not in the surrounding non-tumorous tissue. Cell proliferation was suppressed to 28.6±6.4% in the HLF cells and to 29.8±4.3% in the Hep3B cells at 100 ng shRNA-Fz2 per well. Levels of cyclin D1 expression decreased to 65.2±5.9% in the HLF cells and to 60.8±14.6% in the Hep3B cells at 2.5 μg per well. In conclusion, Fz2 was upregulated in the HCC cells. shRNA-Fz2 suppressed the proliferation of the Hep3B and HLF cells, decreasing Fz2 expression. As it was not expressed in the surrounding non-tumorous tissue, Fz2 may be an ideal molecular therapeutic target for HCC.

Citing Articles

FZD2 regulates cell proliferation and invasion in tongue squamous cell carcinoma.

Huang L, Luo E, Xie J, Gan R, Ding L, Su B Int J Biol Sci. 2019; 15(11):2330-2339.

PMID: 31595151 PMC: 6775310. DOI: 10.7150/ijbs.33881.

References
1.
Jessen J . Noncanonical Wnt signaling in tumor progression and metastasis. Zebrafish. 2009; 6(1):21-8. DOI: 10.1089/zeb.2008.0571. View

2.
Takahashi-Yanaga F . Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol. 2013; 86(2):191-9. DOI: 10.1016/j.bcp.2013.04.022. View

3.
Zeng G, Germinaro M, Micsenyi A, Monga N, Bell A, Sood A . Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 2006; 8(4):279-89. PMC: 1600679. DOI: 10.1593/neo.05607. View

4.
Tomizawa M, Yokosuka O . Picropodophyllin suppresses the proliferation and invasion of hepatocellular carcinoma under serum starvation. Mol Med Rep. 2011; 1(5):685-8. DOI: 10.3892/mmr_00000013. View

5.
Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A . Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer. 2009; 8:90. PMC: 2770486. DOI: 10.1186/1476-4598-8-90. View